MedPath

Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery

Phase 3
Completed
Conditions
Burns
Interventions
Registration Number
NCT03513406
Lead Sponsor
University of Kansas Medical Center
Brief Summary

The purpose of this study is to learn if there is a difference in recovery time when using sugammadex versus neostigmine. The researchers also hope to add further knowledge and data to the safety of using sugammadex in burn patients who are hypermetabolic.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
7
Inclusion Criteria
  • Undergoing burn surgery under general anesthesia
Exclusion Criteria
  • Patients without a non-burned upper extremity
  • Renal insufficiency or failure
  • Sensitivity or hypersensitivity reaction to sugammadex
  • Liver impairment, neuromuscular degenerative disease or dependence on drugs or alcohol

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SugammadexSugammadexMuscle relaxant reversal will be attained with sugammadex 2 mg/kgm IV.
NeostigmineNeostigmineMuscle relaxant reversal will be attained with neostigmine 50 mcg/kgm plus glycopyrrolate10 mcg/kgm IV.
NeostigmineGlycopyrrolateMuscle relaxant reversal will be attained with neostigmine 50 mcg/kgm plus glycopyrrolate10 mcg/kgm IV.
Primary Outcome Measures
NameTimeMethod
Time to return to a 90% Train of Four (TOF) neuromuscular twitchWithin 24 hours after surgery
Secondary Outcome Measures
NameTimeMethod
Time to discharge from the operating roomWithin 24 hours after surgery
Time to endotracheal extubationWithin 24 hours after surgery

Trial Locations

Locations (1)

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath